Search Results - "Nishina, T."

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer by Yamada, Y., Higuchi, K., Nishikawa, K., Gotoh, M., Fuse, N., Sugimoto, N., Nishina, T., Amagai, K., Chin, K., Niwa, Y., Tsuji, A., Imamura, H., Tsuda, M., Yasui, H., Fujii, H., Yamaguchi, K., Yasui, H., Hironaka, S., Shimada, K., Miwa, H., Hamada, C., Hyodo, I.

“…We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric…”
Get full text

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) by Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Eguchi Nakajima, T., Baba, E., Tsuda, M., Moriwaki, T., Esaki, T., Tsuji, Y., Muro, K., Taira, K., Denda, T., Funai, S., Shinozaki, K., Yamashita, H., Sugimoto, N., Okuno, T., Nishina, T., Umeki, M., Kurimoto, T., Takayama, T., Tsuji, A., Yoshida, M., Hosokawa, A., Shibata, Y., Suyama, K., Okabe, M., Suzuki, K., Seki, N., Kawakami, K., Sato, M., Fujikawa, K., Hirashima, T., Shimura, T., Taku, K., Otsuji, T., Tamura, F., Shinozaki, E., Nakashima, K., Hara, H., Tsushima, T., Ando, M., Morita, S., Boku, N., Hyodo, I.

“…FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with…”
Get full text

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials by Yoshino, T., Cleary, J.M., Van Cutsem, E., Mayer, R.J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H.S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.

“…The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI)…”
Get full text

Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection by Nasu, J, Doi, T, Endo, H, Nishina, T, Hirasaki, S, Hyodo, I

“…Endoscopic mucosal resection (EMR) of early gastric cancer is a minimally invasive procedure. The incidence and characteristics of metachronous multiple…”
Get more information

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors by Yamamoto, N., Murakami, H., Nishina, T., Hirashima, T., Sugio, K., Muro, K., Takahashi, T., Naito, T., Yasui, H., Akinaga, S., Koh, Y., Boku, N.

“…Tivantinib (formerly ARQ 197) is a selective inhibitor of c-Met mainly metabolized by CYP2C19. CYP2C19 is known for genetic polymorphisms, and ∼20% of Asians…”
Get full text

Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer by Kadowaki, S., Izawa, N., Minashi, K., Nishina, T., Yamanaka, T., Muro, K., Sunakawa, Y., Hironaka, S., Kajiwara, T., Kawakami, Y., Nakajima, T.

Get full text

SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer by Watanabe, J., Sato, T., Kagawa, Y., Oki, E., Kuboki, Y., Ikeda, M., Ueno, H., Kato, T., Kusumoto, T., Masuishi, T., Yamaguchi, K., Kanazawa, A., Nishina, T., Uetake, H., Yamanaka, T., Yoshino, T.

Get full text

Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial by Doi, T., Iwasa, S., Muro, K., Satoh, T., Hironaka, S., Esaki, T., Nishina, T., Hara, H., Machida, N., Komatsu, Y., Shimada, Y., Otsu, S., Shimizu, S., Chand, V., Watanabe, M.

Get full text

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912 by Yamada, Y., Boku, N., Nishina, T., Yamaguchi, K., Denda, T., Tsuji, A., Hamamoto, Y., Konishi, K., Tsuji, Y., Amagai, K., Ohkawa, S., Fujita, Y., Nishisaki, H., Kawai, H., Takashima, A., Mizusawa, J., Nakamura, K., Ohtsu, A.

“…Since the best chemotherapy regimen for each patient with advanced gastric cancer is uncertain, we aimed to identify molecular prognostic or predictive…”
Get full text

A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX) by Chin, K., Takashima, A., Minashi, K., Kadowaki, S., Nishina, T., Nakajima, T.E., Amagai, K., Machida, N., Gotoh, M., Taku, K., Ishizuka, N., Takahari, D.

Get full text

Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study by Narita, Y, Matsushima, T, Sakamoto, Y, Matsuoka, H, Tanioka, H, Kawakami, T, Shoji, H, Mizukami, T, Izawa, N, Nishina, T, Yamamoto, Y, Mitani, S, Nakamura, M, Misumi, T, Muro, K

“…Nivolumab therapy is a standard-of-care treatment for heavily pretreated patients with advanced gastric cancer (AGC). Previous studies have reported…”
Get full text

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer by Matsubara, J, Nishina, T, Yamada, Y, Moriwaki, T, Shimoda, T, Kajiwara, T, Nakajima, T E, Kato, K, Hamaguchi, T, Shimada, Y, Okayama, Y, Oka, T, Shirao, K

“…Using laser-captured microdissection and a real-time RT–PCR assay, we quantitatively evaluated mRNA levels of the following biomarkers in paraffin-embedded…”
Get full text

A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer by Kagawa, Y., Kato, T., Bando, H., Akagi, K., Denda, T., Nishina, T., Komatsu, Y., Oki, E., Kudo, T., Yamanaka, T., Yoshino, T.

Get full text

Identification of the Novel Inflammation Regulatory Mechanism through MIR-139-5P in Primary Biliary Cirrhosis by Katsumi, T, Nishina, T, Mizuno, K, Haga, H, Okumoto, K, Saito, T, Ueno, Y

Get full text

Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study by Oki, E., Watanabe, J., Sato, T., Kagawa, Y., Kuboki, Y., Ikeda, M., Ueno, H., Kato, T., Kusumoto, T., Masuishi, T., Yamaguchi, K., Kanazawa, A., Nishina, T., Uetake, H., Yamanaka, T., Yoshino, T.

“…Recent advances in adjuvant chemotherapy for early colon cancer have widened physicians' recommendations on the regimen and duration (3 or 6 months) of the…”
Get full text

BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703) by Kotani, D., Bando, H., Masuishi, T., Komatsu, Y., Yamaguchi, K., Nakajima, T.E., Satoh, T., Nishina, T., Esaki, T., Nomura, S., Sakamoto, S., Iida, S., Matsuda, S., Yonemura, M., Fuse, N., Sato, A., Fujii, S., Ebi, H., Ohtsu, A., Yoshino, T.

Get full text

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer by Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T

“…Background: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with…”
Get full text

BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701) by Masuishi, T., Taniguchi, H., Kotani, D., Bando, H., Komatsu, Y., Yamaguchi, K., Nakajima, T.E., Satoh, T., Nishina, T., Esaki, T., Wakabayashi, M., Nomura, S., Sakamoto, S., Ono, H., Hirano, N., Fujishiro, N., Fuse, N., Sato, A., Ohtsu, A., Yoshino, T.

Get full text

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis by M. Imai, Y. Nakamura, T. Denda, Y. Komatsu, S. Yuki, T. Nishina, Y. Hamamoto, H. Hara, T. Esaki, H. Kawakami, K. Kato, T. Satoh, N. Okano, Y. Sunakawa, H. Taniguchi, K. Yamaguchi, T. Yamada, I. Miki, M. Wakabayashi, T. Kuwata, K. Shitara, T. Yoshino

“…Background: The programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1)/programmed cell death-ligand 2 (PD-L2) axis is responsible for…”
Get full text

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) by Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.

“…The purpose of this prospective study was to assess the ability of plasma vascular endothelial growth factor-A short isoforms (pVEGF-Asi) to predict…”
Get full text